Literature DB >> 26816017

The Clearer BENEFITS of Belatacept.

Eliot Heher1, James F Markmann.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26816017     DOI： 10.1056/NEJMe1515765

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig.

Authors:  I R Badell; G M La Muraglia; D Liu; M E Wagener; G Ding; M L Ford
Journal:  Am J Transplant       Date:  2017-08-14       Impact factor: 8.086

Review 2.  Advances in the immunology of heart transplantation.

Authors:  Joren C Madsen
Journal:  J Heart Lung Transplant       Date:  2017-10-20       Impact factor: 10.247

3.  Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.

Authors:  Claire Leibler; Allan Thiolat; Carole Hénique; Chloé Samson; Caroline Pilon; Marie Tamagne; France Pirenne; Benoit Vingert; José L Cohen; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2018-01-10       Impact factor: 10.121

4.  mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.

Authors:  Cyd M Castro-Rojas; Alzbeta Godarova; Tiffany Shi; Sarah A Hummel; Adele Shields; Simon Tremblay; Rita R Alloway; Michael B Jordan; E Steve Woodle; David A Hildeman
Journal:  Transplantation       Date:  2020-05       Impact factor: 4.939

5.  Belatacept and CD28 Costimulation Blockade: Preventingand Reducing Alloantibodies over the Long Term.

Authors:  Ronald F Parsons; Christian P Larsen; Thomas C Pearson; I Raul Badell
Journal:  Curr Transplant Rep       Date:  2019-11-02

6.  Superior inhibition of alloantibody responses with selective CD28 blockade is CTLA-4 dependent and T follicular helper cell specific.

Authors:  Glenn Michael La Muraglia; Susan Zeng; Emma S Crichton; Maylene E Wagener; Mandy L Ford; Idelberto Raul Badell
Journal:  Am J Transplant       Date:  2020-06-11       Impact factor: 8.086

7.  Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial.

Authors:  Idelberto R Badell; Ronald F Parsons; Geeta Karadkhele; Octav Cristea; Sue Mead; Shine Thomas; Jennifer M Robertson; Grace S Kim; John J Hanfelt; Stephen O Pastan; Christian P Larsen
Journal:  Am J Transplant       Date:  2021-03-17       Impact factor: 9.369

8.  Belatacept Conversion in Kidney After Liver Transplantation.

Authors:  Octav Cristea; Geeta Karadkhele; William H Kitchens; Payaswini Vasanth; Christian P Larsen; Idelberto R Badell
Journal:  Transplant Direct       Date:  2021-10-22

9.  Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.

Authors:  James S Young; Stella H-W Khiew; Jinghui Yang; Augustin Vannier; Dengping Yin; Roger Sciammas; Maria-Luisa Alegre; Anita S Chong
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.